{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:50:41Z","timestamp":1787878241103,"version":"build-2784847793"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T00:00:00Z","timestamp":1467072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s13318-016-0350-5","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T02:20:54Z","timestamp":1467080454000},"page":"417-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives"],"prefix":"10.1007","volume":"42","author":[{"given":"Monique","family":"Groen-Wijnberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Krauwinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Kerbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Tretter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"van Gelderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,28]]},"reference":[{"issue":"5 Suppl 1","key":"350_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0090-4295(02)01784-3","volume":"60","author":"AJ Wein","year":"2002","unstructured":"Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7\u201312.","journal-title":"Urology"},{"issue":"2","key":"350_CR2","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.106.115840","volume":"321","author":"T Takasu","year":"2007","unstructured":"Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective \u03b23-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642\u20137.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"350_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/nau.20404","volume":"26","author":"C Yamaguchi","year":"2007","unstructured":"Yamaguchi C, Sakakibara R, Uchiyama T, Yamamoto T, Ito T, Liu Z, et al. Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol Urodyn. 2007;26(6):807\u201313.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"350_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00345-013-1175-3","volume":"32","author":"G Palleschi","year":"2014","unstructured":"Palleschi G, Pastore AL, Maggioni C, Fuschi A, Pacini L, Petrozza V, et al. Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation. World J Urol. 2014;32(4):1021\u20135.","journal-title":"World J Urol"},{"issue":"2","key":"350_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/sj.clpt.6100275","volume":"83","author":"Y Shu","year":"2008","unstructured":"Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008;83(2):273\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"350_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/clpt.2008.61","volume":"84","author":"IS Song","year":"2008","unstructured":"Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84(5):559\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"350_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/cpt1974154424","volume":"15","author":"A Breckenridge","year":"1974","unstructured":"Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther. 1974;15(4):424\u201330.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"350_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","volume":"73","author":"LS Kaminsky","year":"1997","unstructured":"Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67\u201374.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"350_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1021\/tx00025a009","volume":"5","author":"AE Rettie","year":"1992","unstructured":"Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992;5(1):54\u20139.","journal-title":"Chem Res Toxicol"},{"issue":"11","key":"350_CR10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1124\/dmd.104.000182","volume":"32","author":"B Wang","year":"2004","unstructured":"Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004;32(11):1209\u201312.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"350_CR11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","volume":"42","author":"S Takusagawa","year":"2012","unstructured":"Takusagawa S, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective \u03b23-adrenoceptor agonist. Xenobiotica. 2012;42(12):1187\u201396.","journal-title":"Xenobiotica"},{"key":"350_CR12","unstructured":"Sawamoto T, Lee J, Alak A, Meijer J, Roy M, Zha J et al. Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects. Clin Pharmacol Ther 2011; 89(Suppl. 1)(2S21):Abstr. PI-43."},{"issue":"Suppl 1","key":"350_CR13","first-page":"S88","volume":"85","author":"EM Gelderen van","year":"2009","unstructured":"van Gelderen EM, Li Q, Meijer J, Schaddelee MP, Takusagawa S, Sugawara T, et al. An exploratory comparison of the single dose pharmacokinetics of the \u03b23-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther. 2009;85(Suppl 1):S88.","journal-title":"Clin Pharmacol Ther"},{"key":"350_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jchromb.2012.01.018","volume":"887\u2013888","author":"R Teijlingen Van","year":"2012","unstructured":"Van Teijlingen R, Meijer J, Takusagawa S, van Gelderen M, van den Beld C, Usui T. Development and validation of LC\u2013MS\/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;887\u2013888:102\u201311.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"350_CR15","unstructured":"US Food and Drug Administration (FDA). Guidance for industry. Drug interaction studies\u2014study design, data analysis, and implications for dosing and labelling. 2012. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf . Accessed 7 Mar 2016."},{"key":"350_CR16","unstructured":"European Medicines Agency. CHMP Guideline on the investigation of bioequivalence. 2010. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf . Accessed 7 Mar 2016."},{"issue":"11","key":"350_CR17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1177\/009127000004001113","volume":"40","author":"RA Cicco Di","year":"2000","unstructured":"Di Cicco RA, Allen A, Carr A, Fowles S, Jorkasky DK, Freed MI. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol. 2000;40(11):1280\u20135.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"350_CR18","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","volume":"34","author":"W Krauwinkel","year":"2012","unstructured":"Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, et al. Pharmacokinetic properties of mirabegron, a \u03b23-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012;34(10):2144\u201360.","journal-title":"Clin Ther"},{"issue":"3","key":"350_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215\u201336.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"350_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/cpdd.37","volume":"2","author":"WJJ Krauwinkel","year":"2013","unstructured":"Krauwinkel WJJ, Kerbusch VMM, Meijer J, Tretter R, Strabach G, Van Gelderen EM. Evaluation of the pharmacokinetic interaction between the \u03b23-adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(3):255\u201363.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"350_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/clpt.2012.181","volume":"92","author":"M Malik","year":"2012","unstructured":"Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696\u2013706.","journal-title":"Clin Pharmacol Ther"},{"key":"350_CR22","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf . Accessed 14 Mar 2016."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-016-0350-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0350-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0350-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-016-0350-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T01:39:23Z","timestamp":1692409163000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-016-0350-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,28]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1007\/s13318-016-0350-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,28]]}}}